Why the study?
Patient nonadherence to guideline-recommended long-term pharmacologic secondary preventative therapies after ACS is multifactorial.
How can patient adherence to secondary prevention therapies be improved after an acute coronary syndrome?
How can patient adherence to secondary prevention therapies be improved after an acute coronary syndrome?
Improving adherence to secondary prevention therapies after ACS requires a multifaceted approach involving early follow-up, patient education, and novel interventions.
May warrant multifaceted post-ACS adherence strategies now; leaves open optimal components for prospective trials.
Patient nonadherence to guideline-recommended long-term pharmacologic secondary preventative therapies after ACS is multifactorial. A comprehensive multifaceted approach should be implemented to improve adherence and clinical outcomes. This approach should include key interventions such as early follow-up visits, high medication adherence at 90 days, patient engagement and education, and development of novel interventions that support the 3 broad categories influencing patient adherence as discussed in this review.
No takes yet. Share an insight, caveat, or question.
Bahit et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: